

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

04 Jun 2026

### Clinical trial of the effect of “Biebersteinia Multifida root” on quality of life in patients with systolic heart failure

#### Protocol summary

##### Study aim

Evaluation of the effect of Biebersteinia Multifida root extract on quality of life in patients with systolic heart failure

##### Design

This study is a randomized, double-blind clinical trial with parallel groups in which 60 patients are randomly divided into two case-control groups

##### Settings and conduct

Sixty patients with systolic heart failure were selected in the special cardiovascular clinic of Zanjan University of Medical Sciences and randomly divided into two equal groups of 30 people. Patients in the intervention and control groups receive 250 mg of Biebersteinia Multifida root extract and placebo per capsule every 12 hours, respectively. During the study, patients are examined every two weeks. Participants and researcher are blind and not a blind statistic consultant

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Informed consent to participate in the study, Age 40 to 75, Systolic heart failure with ejection fraction equal or lesser than 40 percent, Continuing heart medications prescribed by cardiologist. Exclusion criteria: Pregnancy, Breast feeding, Malignancy, Allergy to Biebersteinia Multifida root extract, Unwillingness of the patient to continue cooperation, Chronic inflammatory disease, Severe renal failure, Collagen vascular disease, Severe liver disease, Acute infectious disease, Decompensated heart failure

##### Intervention groups

Biebersteinia Multifida root extract: Each patient in the intervention group takes a capsule for two months and every twelve hours Placebo: Each patient in the intervention group takes a capsule for two months and every 12 hours

##### Main outcome variables

Quality of life score in the Minnesota Questionnaire; The distance traveled in six minute walk test.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20180130038565N1**

Registration date: **2018-02-19, 1396/11/30**

Registration timing: **prospective**

Last update: **2018-02-19, 1396/11/30**

Update count: **0**

##### Registration date

2018-02-19, 1396/11/30

##### Registrant information

##### Name

Ebadollah salekmoghadam

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 24 3313 1559

##### Email address

salekmoghadam@zums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2018-03-01, 1396/12/10

##### Expected recruitment end date

2018-09-22, 1397/06/31

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Clinical trial of the effect of “Biebersteinia Multifida root” on quality of life in patients with systolic heart failure

### Public title

Biebersteinia Multifida root in systolic heart failure

### Purpose

Treatment

### Inclusion/Exclusion criteria

#### Inclusion criteria:

Informed consent to participate in the study Age 40 to 75 Systolic heart failure with ejection fraction equal or lesser than 40 percent Continuing heart medications, prescribed by cardiologist

#### Exclusion criteria:

Pregnancy Breast feeding Malignancy Allergy to Biebersteinia Multifida root extract Unwillingness of the patient to continue cooperation Chronic inflammatory disease Severe renal failure Collagen vascular disease Severe liver disease Acute infectious disease Decompensated heart failure

### Age

From **40 years** old to **75 years** old

### Gender

Both

### Phase

3

### Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor

### Sample size

Target sample size: **60**

### Randomization (investigator's opinion)

Randomized

### Randomization description

By using random numbers table, patients are divided in two 30 person case-control groups

### Blinding (investigator's opinion)

Double blinded

### Blinding description

All participants and researchers are blind in this study ,coding of medicine and placebo are under the responsibility of a statistical adviser who is not blind

### Placebo

Used

### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Zanjan University of Medical

Sciences

### Street address

Ethics committee, Zanjan University of Medical Sciences, Azadi sq., Jomhuri Islami Ave.

### City

Zanjan

### Province

Zanjan

### Postal code

4515613191

### Approval date

2018-01-23, 1396/11/03

### Ethics committee reference number

IR.ZUMS.REC.1396.273

## Health conditions studied

### 1

#### Description of health condition studied

Systolic heart failure

#### ICD-10 code

I50.2

#### ICD-10 code description

Systolic (congestive) heart failure

## Primary outcomes

### 1

#### Description

Quality of Life Score in the Minnesota Questionnaire

#### Timepoint

Measure the quality of life score at the beginning of study (before intervention) and one week after taking the Biebersteinia Multifida root extract.

#### Method of measurement

Minnesota Living With Heart Failure Questionnaire

### 2

#### Description

The distance traveled in six minute walk test

#### Timepoint

Measure the distance traveled in six minute walk test at the beginning of study (before intervention) and one week after taking the Biebersteinia Multifida root extract

#### Method of measurement

Six minute walk test

## Secondary outcomes

### 1

#### Description

Left ventricular ejection fraction

#### Timepoint

Measurement of left ventricular ejection fraction at the beginning of study (before intervention)

#### Method of measurement

Echocardiography

## 2

### **Description**

Complete blood count

### **Timepoint**

Measurement of complete blood count at the beginning of study (before intervention) and one week after taking the Biebersteinia Multifida Root Extract

### **Method of measurement**

Blood test

## 3

### **Description**

Blood urea nitrogen

### **Timepoint**

Measurement of blood urea nitrogen at the beginning of study (before intervention) and one week after taking the Biebersteinia Multifida Root Extract

### **Method of measurement**

Blood test

## 4

### **Description**

Serum creatinine

### **Timepoint**

Measurement of serum creatinine at the beginning of study (before intervention) and one week after taking the Biebersteinia Multifida Root Extract

### **Method of measurement**

Blood test

## 5

### **Description**

Alanine aminotransferase

### **Timepoint**

Measurement of Alanine aminotransferase at the beginning of study (before intervention) and one week after taking the Biebersteinia Multifida Root Extract

### **Method of measurement**

Blood test

## 6

### **Description**

Aspartate aminotransferase

### **Timepoint**

Measurement of Aspartate aminotransferase at the beginning of study (before intervention) and one week after taking the Biebersteinia Multifida Root Extract

### **Method of measurement**

Blood test

## 7

### **Description**

Alkaline phosphatase

### **Timepoint**

Measurement of Alkaline phosphatase at the beginning of study (before intervention) and one week after taking the Biebersteinia Multifida Root Extract

### **Method of measurement**

Blood test

## 8

### **Description**

C-reactive protein

### **Timepoint**

Measurement of C-reactive protein at the beginning of study (before intervention) and one week after taking the Biebersteinia Multifida Root Extract

### **Method of measurement**

Blood test

## **Intervention groups**

### 1

#### **Description**

Intervention group: Dry extract of Biebersteinia Multifida root with a concentration of 10 percent relative to 100 g of roots of the plant, has been standardized 250 mg per capsule at the school of Pharmacy of Shahid Beheshti University of Medical Sciences. The drug is given one capsule every 12 hours for 60 days to volunteer patients with systolic heart failure who have ejection fraction equal to or less than 40 percent.

#### **Category**

Treatment - Drugs

### 2

#### **Description**

Control group: Placebo in the control group contains starch corn which is provided in capsules and boxes of the same intervention group at the school of Pharmacy of Shahid Beheshti University of Medical Sciences. The placebo is given one capsule every 12 hours for 60 days to volunteer patients with heart failure who have ejection fraction equal to or less than 40 percent.

#### **Category**

Placebo

## **Recruitment centers**

### 1

#### **Recruitment center**

##### **Name of recruitment center**

Special clinic of cardiovascular diseases of Zanjan University of Medical Sciences

##### **Full name of responsible person**

Ebadollah Salekmoghadam

##### **Street address**

Special clinic of cardiovascular disease of Zanjan University of Medical Sciences, Amin doctors' building, Haft tir st.

##### **City**

Zanjan

##### **Province**

Zanjan

##### **Postal code**

4518617384

**Phone**

+98 24 3356 5333

**Email**

ahanghar@zums.ac.ir

## Sponsors / Funding sources

### 1

**Sponsor****Name of organization / entity**

Zanjan University of Medical Sciences

**Full name of responsible person**

Alireza Shoghli

**Street address**

Deputy of Research and Technology, Zanjan University of Medical Sciences, Azadi sq., Jomhuri Islami Ave.

**City**

Zanjan

**Province**

Zanjan

**Postal code**

4515613191

**Phone**

+98 24 3342 0677

**Fax**

+98 24 3342 4770

**Email**

shoghli@zums.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Zanjan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

**Contact****Name of organization / entity**

Zanjan University of Medical Sciences

**Full name of responsible person**

Ebadollah Salekmoghadam

**Position**

Ph.D student of Iranian Medicine

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Traditional Medicine

**Street address**

Education and Treatment Center of Valiasr, Valiasr sq.

**City**

Zanjan

**Province**

Zanjan

**Postal code**

4515777978

**Phone**

+98 24 3377 0801

**Fax**

+98 24 3377 0757

**Email**

salekmoghadam@zums.ac.ir

## Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Zanjan University of Medical Sciences

**Full name of responsible person**

Hassan Ahangar

**Position**

Associate professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Cardiology

**Street address**

Special clinic of cardiovascular disease of Zanjan University of Medical Sciences, Amin doctors' building, Haft tir st.

**City**

Zanjan

**Province**

Zanjan

**Postal code**

4518617384

**Phone**

+98 24 3356 5333

**Email**

ahanghar@zums.ac.ir

## Person responsible for updating data

**Contact****Name of organization / entity**

Zanjan University of Medical Sciences

**Full name of responsible person**

Ebadollah Salekmoghadam

**Position**

Ph.D student of Iranian Medicine

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Traditional Medicine

**Street address**

Education and Treatment Center of Valiasr, Valiasr sq.

**City**

Zanjan

**Province**

Zanjan

**Postal code**

4515777978

**Phone**

+98 24 3377 0801

**Email**

salekmoghadam@zums.ac.ir

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to

make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available